Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma.
Marco LodriniJosefine GraefTheresa M Thole-KlieschKathy AstrahantseffAnnika SprüsselMaddalena GrimaldiConstantin PeitzRasmus B LinkeJan F HollanderErwin LankesAnnette KünkeleLena OevermannGeorg SchwabeJörg FuchsAnnabell Krienelke-SzymanskyJohannes Hubertus SchultePatrick HundsdörferCornelia EckertHolger AmthauerAngelika EggertHedwig E DeubzerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Tumor-specific alterations can be identified and monitored during disease course in liquid biopsies from pediatric patients with high-risk neuroblastoma. This approach to cfDNA surveillance warrants further prospective validation and exploitation for diagnostic purposes and to guide therapeutic decisions.